Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Goodwill (2016 - 2025)

Historic Goodwill for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $9.5 million.

  • Harvard Bioscience's Goodwill fell 8341.72% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year decrease of 8341.72%. This contributed to the annual value of $56.3 million for FY2024, which is 129.85% down from last year.
  • Harvard Bioscience's Goodwill amounted to $9.5 million in Q3 2025, which was down 8341.72% from $10.2 million recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Goodwill peaked at $58.4 million during Q2 2021, and registered a low of $9.0 million during Q1 2025.
  • Its 5-year average for Goodwill is $49.4 million, with a median of $56.6 million in 2024.
  • As far as peak fluctuations go, Harvard Bioscience's Goodwill surged by 257.38% in 2021, and later tumbled by 8419.73% in 2025.
  • Quarter analysis of 5 years shows Harvard Bioscience's Goodwill stood at $57.7 million in 2021, then decreased by 2.48% to $56.3 million in 2022, then grew by 1.43% to $57.1 million in 2023, then dropped by 1.3% to $56.3 million in 2024, then plummeted by 83.09% to $9.5 million in 2025.
  • Its Goodwill stands at $9.5 million for Q3 2025, versus $10.2 million for Q2 2025 and $9.0 million for Q1 2025.